Assyro AI

Orange Book product · Brand (NDA)

ORKAMBI

IVACAFTOR; LUMACAFTOR

Brand (NDA)NDA 206038RX VERTEX PHARMS INC

At a glance

Sep 28, 2016

Approved

Brand (NDA)

Application

Not listed

TE code

44

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Sep 28, 2016

    9 yr 10 mo ago

  2. Today

  3. Patent 7973038 expires

    Listed method-of-use patent (U-1973) expiration.

    Nov 08, 2026

    in 5 mo

  4. Patent 8741933 expires

    Listed method-of-use patent (U-1909) expiration.

    Nov 08, 2026

    in 5 mo

  5. Patent 9216969 expires

    Listed drug product patent expiration.

    Nov 08, 2026

    in 5 mo

  6. Patent 8410274 expires

    Listed drug product patent expiration.

    Dec 28, 2026

    in 6 mo

  7. Patent 8754224 expires

    Listed drug substance patent expiration.

    Dec 28, 2026

    in 6 mo

  8. Patent 9670163 expires

    Listed drug product patent expiration.

    Dec 28, 2026

    in 6 mo

  9. Patent 9931334 expires

    Listed drug product patent expiration.

    Dec 28, 2026

    in 6 mo

  10. Patent 7973038*PED expires

    Listed listed patent expiration.

    May 08, 2027

    in 11 mo

  11. Patent 8741933*PED expires

    Listed listed patent expiration.

    May 08, 2027

    in 11 mo

  12. Patent 9216969*PED expires

    Listed listed patent expiration.

    May 08, 2027

    in 11 mo

  13. Patent 7495103 expires

    Listed drug substance patent expiration.

    May 20, 2027

    in 11 mo

  14. Patent 8410274*PED expires

    Listed listed patent expiration.

    Jun 28, 2027

    in 1 yr

  15. Patent 8754224*PED expires

    Listed listed patent expiration.

    Jun 28, 2027

    in 1 yr

  16. Patent 9670163*PED expires

    Listed listed patent expiration.

    Jun 28, 2027

    in 1 yr

  17. Patent 9931334*PED expires

    Listed listed patent expiration.

    Jun 28, 2027

    in 1 yr

  18. Patent 8324242 expires

    Listed method-of-use patent (U-1911) expiration.

    Aug 05, 2027

    in 1 yr 2 mo

  19. Patent 7495103*PED expires

    Listed listed patent expiration.

    Nov 20, 2027

    in 1 yr 5 mo

  20. Patent 8324242*PED expires

    Listed listed patent expiration.

    Feb 05, 2028

    in 1 yr 8 mo

  21. Patent 10597384 expires

    Listed drug substance patent expiration.

    Dec 04, 2028

    in 2 yr 6 mo

  22. Patent 11052075 expires

    Listed drug product patent expiration.

    Dec 04, 2028

    in 2 yr 6 mo

  23. Patent 12065432 expires

    Listed method-of-use patent (U-3984) expiration.

    Dec 04, 2028

    in 2 yr 6 mo

  24. Patent 8653103 expires

    Listed drug product patent expiration.

    Dec 04, 2028

    in 2 yr 6 mo

  25. Patent 9150552 expires

    Listed method-of-use patent (U-1908) expiration.

    Dec 04, 2028

    in 2 yr 6 mo

  26. Patent 10597384*PED expires

    Listed listed patent expiration.

    Jun 04, 2029

    in 3 yr

  27. Patent 11052075*PED expires

    Listed listed patent expiration.

    Jun 04, 2029

    in 3 yr

  28. Patent 12065432*PED expires

    Listed listed patent expiration.

    Jun 04, 2029

    in 3 yr

  29. Patent 8653103*PED expires

    Listed listed patent expiration.

    Jun 04, 2029

    in 3 yr

  30. Patent 9150552*PED expires

    Listed listed patent expiration.

    Jun 04, 2029

    in 3 yr

  31. Patent 8846718 expires

    Listed method-of-use patent (U-1908) expiration.

    Jul 02, 2029

    in 3 yr 1 mo

  32. Patent 10646481 expires

    Listed drug product patent expiration.

    Aug 13, 2029

    in 3 yr 2 mo

  33. Patent 11564916 expires

    Listed method-of-use patent (U-3529) expiration.

    Aug 13, 2029

    in 3 yr 2 mo

  34. Patent 12458635 expires

    Listed drug product patent expiration.

    Aug 13, 2029

    in 3 yr 2 mo

  35. Patent 9192606 expires

    Listed drug product patent expiration.

    Sep 29, 2029

    in 3 yr 4 mo

  36. Patent 8846718*PED expires

    Listed listed patent expiration.

    Jan 02, 2030

    in 3 yr 7 mo

  37. Patent 10646481*PED expires

    Listed listed patent expiration.

    Feb 13, 2030

    in 3 yr 9 mo

  38. Patent 11564916*PED expires

    Listed listed patent expiration.

    Feb 13, 2030

    in 3 yr 9 mo

  39. Patent 12458635*PED expires

    Listed listed patent expiration.

    Feb 13, 2030

    in 3 yr 9 mo

  40. Patent 9192606*PED expires

    Listed listed patent expiration.

    Mar 29, 2030

    in 3 yr 10 mo

  41. Patent 8507534 expires

    Listed drug substance patent expiration.

    Sep 20, 2030

    in 4 yr 4 mo

  42. Patent 8716338 expires

    Listed drug product patent expiration.

    Sep 20, 2030

    in 4 yr 4 mo

  43. Patent 8993600 expires

    Listed drug product patent expiration.

    Dec 11, 2030

    in 4 yr 7 mo

  44. Patent 8507534*PED expires

    Listed listed patent expiration.

    Mar 20, 2031

    in 4 yr 10 mo

  45. Patent 8716338*PED expires

    Listed listed patent expiration.

    Mar 20, 2031

    in 4 yr 10 mo

  46. Patent 8993600*PED expires

    Listed listed patent expiration.

    Jun 11, 2031

    in 5 yr 1 mo

Pharmaceutical detail

Active ingredient

IVACAFTOR; LUMACAFTOR

Strength

125MG;100MG

Dosage form

TABLET

Route

ORAL

TE code

Not listed

Application

NDA 206038

Product number

002

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (44)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
7973038Nov 08, 2026in 5 mo
U-1973
8741933Nov 08, 2026in 5 mo
U-1909
9216969Nov 08, 2026in 5 mo
Product
8410274Dec 28, 2026in 6 mo
Product
8754224Dec 28, 2026in 6 mo
SubstanceProduct
9670163Dec 28, 2026in 6 mo
ProductU-1911
9931334Dec 28, 2026in 6 mo
ProductU-2276
7973038*PEDMay 08, 2027in 11 mo
8741933*PEDMay 08, 2027in 11 mo
9216969*PEDMay 08, 2027in 11 mo
7495103May 20, 2027in 11 mo
SubstanceProduct
8410274*PEDJun 28, 2027in 1 yr
8754224*PEDJun 28, 2027in 1 yr
9670163*PEDJun 28, 2027in 1 yr
9931334*PEDJun 28, 2027in 1 yr
8324242Aug 05, 2027in 1 yr 2 mo
U-1911
7495103*PEDNov 20, 2027in 1 yr 5 mo
8324242*PEDFeb 05, 2028in 1 yr 8 mo
10597384Dec 04, 2028in 2 yr 6 mo
SubstanceProductU-2777
11052075Dec 04, 2028in 2 yr 6 mo
ProductU-3181
12065432Dec 04, 2028in 2 yr 6 mo
U-3984
8653103Dec 04, 2028in 2 yr 6 mo
Product
9150552Dec 04, 2028in 2 yr 6 mo
U-1908
10597384*PEDJun 04, 2029in 3 yr
11052075*PEDJun 04, 2029in 3 yr
12065432*PEDJun 04, 2029in 3 yr
8653103*PEDJun 04, 2029in 3 yr
9150552*PEDJun 04, 2029in 3 yr
8846718Jul 02, 2029in 3 yr 1 mo
U-1908
10646481Aug 13, 2029in 3 yr 2 mo
Product
11564916Aug 13, 2029in 3 yr 2 mo
U-3529
12458635Aug 13, 2029in 3 yr 2 mo
ProductU-4338
9192606Sep 29, 2029in 3 yr 4 mo
ProductU-1912
8846718*PEDJan 02, 2030in 3 yr 7 mo
10646481*PEDFeb 13, 2030in 3 yr 9 mo
11564916*PEDFeb 13, 2030in 3 yr 9 mo
12458635*PEDFeb 13, 2030in 3 yr 9 mo
9192606*PEDMar 29, 2030in 3 yr 10 mo
8507534Sep 20, 2030in 4 yr 4 mo
SubstanceProduct
8716338Sep 20, 2030in 4 yr 4 mo
ProductU-1910
8993600Dec 11, 2030in 4 yr 7 mo
Product
8507534*PEDMar 20, 2031in 4 yr 10 mo
8716338*PEDMar 20, 2031in 4 yr 10 mo
8993600*PEDJun 11, 2031in 5 yr 1 mo
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.